Evidence map›Paper›PMID 24983628›Full record

ArticlePloS one2014

Telomerase variant A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal carcinomas.

Yuwei Zhang, Rodrigo Calado, Mahadev Rao, Julie A Hong, Alan K Meeker, Bogdan Dumitriu, Scott Atay, Peter J McCormick, Susan H Garfield, Danny Wangsa and 14 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. AEndocrine-related cancer · 2017
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 2 countries.

Yuwei ZhangThoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
Rodrigo CaladoNational Heart, Lung, and Blood Institute, Bethesda, Maryland, United States of America.
Mahadev RaoThoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
Julie A HongThoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
Alan K MeekerDepartments of Pathology and Oncology, Johns Hopkins University of Medicine, Baltimore, Maryland, United States of America.
Bogdan DumitriuNational Heart, Lung, and Blood Institute, Bethesda, Maryland, United States of America.
Scott AtayThoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
Peter J McCormickLaboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, United States of America.
Susan H GarfieldLaboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, Maryland, United States of America.
Danny WangsaSection of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, United States of America.
Hesed M Padilla-NashSection of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, United States of America.
Sandra BurkettComparative Molecular Cytogenetics Core Facility, National Cancer Institute, Frederick, Maryland, United States of America.
Mary ZhangThoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
Tricia F KunstThoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
Nathan R PetersonNational Heart, Lung, and Blood Institute, Bethesda, Maryland, United States of America.
Sichuan XiThoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
Suzanne InchausteThoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
Nasser K AltorkiDepartment of Thoracic Surgery, Weill Cornell Medical Center, New York, New York, United States of America.
Alan G CassonDepartment of Surgery, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
David G BeerSection of Thoracic Surgery, University of Michigan Medical Center, Ann Arbor, Michigan, United States of America.
Curtis C HarrisLaboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, Maryland, United States of America.
Thomas RiedSection of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, United States of America.
Neal S YoungNational Heart, Lung, and Blood Institute, Bethesda, Maryland, United States of America.
David S SchrumpThoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
National Cancer Institute · USNational Heart Lung and Blood Institute · USCornell University · USFrederick National Laboratory for Cancer Research · USJohns Hopkins Medicine · USMichigan United · USUniversity of Saskatchewan · CA

Funding

Telomeres DiseasesZIAHL006089 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI YOUNG, NEAL S · 2010 to 2025
$26.2M
p53, Aging, and CancerZIABC011496 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HARRIS, CURTIS · 2013 to 2025
$21.1M
Epigenetic Mechanisms of Gene Expression in Thoracic MalignanciesZIABC011115 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHRUMP, DAVID · 2009 to 2025
$15.1M
Intramural NIH HHS
6 · The paper itself

Abstract

backgroundAlthough implicated in the pathogenesis of several chronic inflammatory disorders and hematologic malignancies, telomerase mutations have not been thoroughly characterized in human cancers. The present study was performed to examine the frequency and potential clinical relevance of telomerase mutations in esophageal carcinomas.

methodsSequencing techniques were used to evaluate mutational status of telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC) in neoplastic and adjacent normal mucosa from 143 esophageal cancer (EsC) patients. MTS, flow cytometry, time lapse microscopy, and murine xenograft techniques were used to assess proliferation, apoptosis, chemotaxis, and tumorigenicity of EsC cells expressing either wtTERT or TERT variants. Immunoprecipitation, immunoblot, immunofluorescence, promoter-reporter and qRT-PCR techniques were used to evaluate interactions of TERT and several TERT variants with BRG-1 and β-catenin, and to assess expression of cytoskeletal proteins, and cell signaling. Fluorescence in-situ hybridization and spectral karyotyping techniques were used to examine telomere length and chromosomal stability.

resultsSequencing analysis revealed one deletion involving TERC (TERC del 341-360), and two non-synonymous TERT variants [A279T (2 homozygous, 9 heterozygous); A1062T (4 heterozygous)]. The minor allele frequency of the A279T variant was five-fold higher in EsC patients compared to healthy blood donors (p<0.01). Relative to wtTERT, A279T decreased telomere length, destabilized TERT-BRG-1-β-catenin complex, markedly depleted β-catenin, and down-regulated canonical Wnt signaling in cancer cells; these phenomena coincided with decreased proliferation, depletion of additional cytoskeletal proteins, impaired chemotaxis, increased chemosensitivity, and significantly decreased tumorigenicity of EsC cells. A279T expression significantly increased chromosomal aberrations in mouse embryonic fibroblasts (MEFs) following Zeocin™ exposure, as well as Li Fraumeni fibroblasts in the absence of pharmacologically-induced DNA damage.

conclusionsA279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal cancer cells. These findings warrant further analysis of A279T expression in esophageal cancers and premalignant esophageal lesions.

Indexed as

Gene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticMutation, MissenseTelomere HomeostasisAmino Acid SubstitutionAnimalsCell Line, TumorEsophageal NeoplasmsFemaleHumansMaleMiceMice, NudeNeoplasm ProteinsRNARNA, NeoplasmNeoplasm ProteinsRNARNA, NeoplasmTelomerasetelomerase RNATERT protein, human

Identifiers

PMID24983628
PMCPMC4077737
OpenAlexW2020861920

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.